INTRODUCTION
The post-genomic (or post-sequencing) era holds the promise of a better understanding and cure of human diseases affecting millions of individuals today, such as cardiovascular and neurodegenerative diseases and cancer. Knowledge of the sequence, structure and organization of our genome is leading to the development of genomewide analytical techniques that give us a broad picture of the structure and activity of our genes during pathological processes. This is providing us with potent tools for understanding the molecular mechanisms underlying diseases, for exploring an unprecedented range of new potential drug targets, and for the molecular classification, diagnosis and prediction of drug sensitivity and risk of recurrence.
As always during the transfer of biological knowledge to medicine and industry, extensive technical developments and support implementations are needed, as well as acquaintance of the operators with the new algorithms and bioinformatics that accompany new analytical tools. This paper will focus on the recent developments in the field of genomewide gene expression profiling of breast cancer as it is proposed today for prognostic and predictive purposes, with contributions derived from the experience acquired in our laboratory.
BREAST CANCER
With one million new cases in the world each year, breast cancer is the most common malignancy in women, accounting for 18% of all female cancers. In the United Kingdom, where the age-standardized incidence and mortality are the highest in the world, the incidence among women aged 50 approaches 2 per 1000 women per year and the disease is the single commonest cause of death among women aged 40-50 years, accounting for about a fifth of the deaths in this age group.
There are more than 14,000 breast cancer-related deaths each year and the breast cancer incidence is in-creasing particularly among women aged 50-64, probably because of breast screening applied to this age group. Of every 1000 women aged 50, two will recently have had breast cancer diagnosed and about 15 will have had a diagnosis before the age of 50, resulting in a prevalence of breast cancer of nearly 2%. The incidence and mortality of the disease vary by up to a factor of five between countries, with a higher incidence being registered in Western countries, indicating that environmental factors (dietary habits, alcohol intake, reproductive factors, etc.) are of major importance. The incidence increases with age, doubling every 10 years until menopause, when the rate of increase drops dramatically, indicating the important contribution of endogenous steroid hormones to breast cancer development. Also exogenous hormones have a recognized role: among current users of HRT and those who ceased use one to four years before, the relative risk of developing breast cancer increases by a factor of 1.023 for each year of use. This is consistent with a delay effect of the onset of menopause, as the RR for breast cancer increases in never-users of HRT by a factor of 1.028 per each year postmenopause. A promising avenue for primary prevention of breast cancer is to influence the hormonal milieu of women at risk: both the tamoxifen and raloxifene studies show a selective reduction in the incidence of estrogen receptor-positive breast cancer (for a review, see 1).
PROGNOSTIC FACTORS
Breast cancer is characterized by early hematogenous dissemination. Therefore, in addition to local management by surgery and radiotherapy, established treatments of breast cancer encompass systemic application of combination chemotherapy and/or endocrine treatment. Patients who receive systemic adjuvant therapy have a substantial disease-free survival and overall survival benefit, as documented by a large number of clinical trials. However, since breast cancer is a heteroge- The diffusion of screening procedures is also leading to an increasing proportion of patients having early detected small tumors with a low risk of recurrence. Today 50-60% of breast cancer patients present with node-negative disease; in the near future, 70-80% of all patients will be node negative. In this setting it will be crucial to distinguish localized disease from occult early systemic disease.
In node-negative breast cancer 70% of all patients are cured by surgery alone and therefore do not need any adjuvant therapy. Ideally, only 30% of all node-negative patients should receive adjuvant treatment. At least 100 factors have been described as having prognostic significance in node-negative breast cancer (2) . However, for many of these factors the available data are inconsistent. Moreover, most factors fail to maintain independent prognostic value in multivariate analysis. The latest St Gallen Consensus Panel stated that patients with very small tumors that are highly differentiated (G1) and steroid hormone receptor positive may be spared adjuvant chemotherapy. However, these patients represent less than 10% of all node-negative breast cancer cases. It would therefore seem necessary to improve the identification of patients who have a very low risk of relapse and do not need any adjuvant therapy.
PREDICTIVE FACTORS
As the efficacy of treatment is likely to be dependent on the biology of each tumor, individualized treatments will require predictive factors derived from the biology of each single tumor. Considering that node-negative breast cancer patients have a 30% risk of recurrence, and that chemotherapy is typically effective in 25% of cancer patients, it can be estimated that only 8% of patients will benefit from adjuvant treatments due to insufficient sensitivity to chemotherapy.
Tumor biology seems to play an important role in the resistance to treatment and should be taken into consideration when adjuvant treatment is selected. For example, the efficacy of adjuvant chemotherapy appears dependent on the c-erbB-2 status (3). Patients with c-erbB-2-negative tumors have no better survival when anthracyclines are used instead of CMF, while anthracyclines might be more effective than CMF in patients with c-erbB-2 overexpression. Another example is constituted by endocrine intervention in tumors that display dependence on hormones for their growth. Today the well-tolerated antiestrogenic therapy is given to postmenopausal patients whose tumors express estrogen receptors (ER). However, only about 50-60% of such patients will benefit from it and 5% to 10% of ER-tumors might also have responded to hormonal therapy. These examples, while demonstrating the clinical usefulness of biological mark-ers, clearly show that there is an urgent need for markers capable of accurately predicting clinical aggressiveness and response to therapy in breast cancer (4) .
BIOLOGY
The heterogeneity and clinical variability of breast cancer reflect the molecular complexity of this disease. Indeed, from a biological and biomolecular point of view breast cancer displays extremely complex features. During the past 20 years we have described dozens of genetic alterations in breast carcinomas, but we have never been able to find a single genetic alteration that is really distinctive of these tumors. Furthermore, molecular alterations do not appear in a traceable order during the different stages of disease and are not organized in recognizable patterns that identify clinically relevant groups, as is the case in colon carcinoma. The cellular and molecular heterogeneity of breast tumors defines a level of complexity that depicts their biology.
A number of molecular markers including ERBB2/neu, MYC, p53, cathepsin D, uPA, PSA, VEGF, EGFR, cyclins D1 and E, and many others (2, 5) have been correlated with prognosis, but they show very limited predictive value in the choice of appropriate treatments. Any researcher in this field who studies one or more molecular parameters has experienced the fact that each marker has intrinsic correlations with other parameters and that its individual prognostic or predictive value increases when examined in appropriate subgroups. Thus, we all agree that only by combining and integrating all the individually limited amounts of information provided by single markers, we could finally reach a valuable description of the biology of individual tumors. Of course, one possibility is to individually measure, in each tumor biopsy, all the numerous variables that have shown some degree of significance, and to analyze them in combination. This approach might prove of value but is unrealistic in a clinical setting because of the cost, labor and time involved.
Great advances in molecular biology, together with the knowledge of the entire sequence of the human genome, have recently led to the development of methods that permit the analysis of the expression level of thousands of genes at once, what we call today gene expression profiling (6, 7) . This method consists in having hundreds or thousands of DNA sequences ("probes") spotted in an ordered array on a solid support. Labeled RNAs (or copies of it) from tumors are then hybridized to this support, obtaining labeled spots whose intensity is proportional to the level of expression of that particular sequence (i.e. gene) in the sample. The extreme evolution of this technique is known as DNA microarrays or DNA chips, microscope slides onto which cDNAs or oligonucleotide probes representing up to 25,000 hu-man genes are orderly arrayed. Fluorochrome-labeled sample RNA hybridization to the array gives fluorescent spots that are quantitatively measured by laser scanning. At present there are two main techniques for microarrays: the first makes use of oligonucleotide probes, 20-25 nucleotides in length, that are directly synthesized on a microscope slide using a photolithographic technique, at a very high density (up to 300,000 different oligos/cm 2 ). The second technique consists of "printing" microscope slides with previously prepared DNA probes, either cDNA or PCR products or oligonucleotides with a length of 50 to 70 nucleotides. Lower densities (up to 25,000 spots/cm 2 ) are obtained with the latter, but there is the advantage that a "sample-versus-control" cohybridization procedure can be used, which is particularly useful when performing one-by-one comparisons, such as tumor versus normal tissue or treated versus untreated cells. Here, sample and control RNAs are labeled with two different fluorochromes (e.g. "red" and "green") and subsequently hybridized together to the microarray. Dual-channel confocal laser scanning allows direct comparison of the amount of each mRNA species present in the sample versus control.
Although we could argue that this gives a picture that lacks information on protein expression, localization and function, tissue morphology etc., RNA analysis has enormous advantages, first of all the fact that the biochemistry of nucleic acids allows linear amplification of sample RNA, scaling down the amount of tissue required for analysis to a few micrograms. It has recently been shown that the material obtained with fine-needle biopsies is sufficient for gene expression profiling on microarrays using RNA amplification procedures (8) .
Gene expression profiling of tumors can be viewed in two ways that we would call "targeted" or "genomewide". Targeted analysis means that we include in the microarray probes for predefined sets of genes, whose participation in cancer development and progression is inferred either from previous research or by logical inference, e.g. genes related to apoptosis or angiogenesis, oncogenes and tumor suppressors, matrix proteases, growth factor receptors, cytokines, or any other group of defined genes. Genomewide analysis, instead, uses unselected probes and tends towards an as complete as possible representation of all the possible expressed genomic sequences. Both approaches have pros and cons and different uses. The genomewide approach can be employed to identify a gene expression profile that is characteristic of a special biological or clinical situation, i.e. to identify the genetic programs that underly particular phenotypes.
In the case of breast cancer characterization, DNA microarray analysis is carried out on a number of tumor biopsies from relevant cases, then the individual gene expression profiles are searched for association with any clinically relevant parameter such as disease-free inter-val, survival or response to therapy, by performing hierarchical clustering analysis (9) . This kind of routine ranks tumors on the basis of the maximum similarity, using an iterative scoring procedure, i.e. taking into account contributions of all the genes analyzed instead of considering individual genes for classification. Genomewide profiling has proved capable of discriminating clinically relevant subgroups of breast cancers. It has been reported, for example, that the gene expression profile measured in breast tumors can easily classify tumors based on biological characteristics, distinguish clinically relevant subgroups, and can predict the risk of distant metastasis much more effectively than any other classical marker or combination of markers (10) (11) (12) (13) . In the discrimination of more aggressive tumors or cases that are responsive to a particular therapy, gene expression profiles are themselves a unique marker, regardless of the genes that compose it.
The "targeted" approach, instead, can be used to verify whether any set of known genes may play a role in a particular phenomenon, for example to find new genes that are relevant for the development of a metastatic phenotype or drug resistance. In our laboratory we have been using filter-based radioactive RNA assays to investigate the role of one hundred genes in predicting the risk of metastasis in breast cancer. For this purpose we used a set of archival tissues from breast cancer patients with complete follow-up and obtained indications regarding the involvement of several of them. In particular, we looked for genes, apart from VEGF, involved in angiogenesis that could correlate with tumor aggressiveness and found indications regarding the involvement of angiopoietin-2 (Ang-2). Ang-2 is a peptide binding to the Tie2 tyrosine kinase receptor expressed on the surface of endothelial cells, which counteracts the effects of Ang-1, resulting in destabilization of existing vessels, i.e. the first step in the neoangiogenic process. Using quantitative real-time RT-PCR and immunohistochemistry, we successively demonstrated that Ang-2 expression is itself an indicator of poor prognosis, independent of lymph node involvement. Ang-2 expression does not correlate with any of the known markers except lymph node involvement, is expressed both in tumor and endothelial cells, and is upregulated in response to estrogens (14) . A shortcoming of Ang-2 is similar to what we have seen in the past for other markers, i.e. its limited prognostic value, but it has biological relevance and may represent a new therapeutic target. Individual values of other genes screened by DNA array are now under study.
Determining the genetic programs that are activated during cell response to stimulatory or inhibitory signals is particularly important. In breast cancer there is an urgent need for markers other than ER to predict responsiveness to antiestrogenic therapies and to identify potential downstream therapeutic targets in ER-responsive tumors.
Genomewide cDNA microarray analysis of estrogen-and antiestrogen-treated breast cancer cells has revealed a group of more than 400 genes whose expression is either increased or decreased in response to the hormone; this group can be divided into subgroups according to the regulation kinetics. One important proof-of-concept was obtained by bioinformatic analysis of these data, comparing them to the data available in public databases relative to either different breast carcinoma cell lines or breast tumors (15) . A subset of 61 genes, among those found to be estrogen-regulated in the experimental model system, was able to correctly identify ER+ cells and tumors, without taking into account the expression level of ER-alpha or beta (16). Expression profiles of these genes are now being tested for predicting the response of breast tumors to neoadjuvant and adjuvant antiestrogenic treatments.
TENS, HUNDREDS, THOUSANDS... BACK TO TENS?
One important point to be gleaned from microarray studies of tumors is that by extending the range of our investigation from tens to hundreds or thousands of genes, we can perceive a number of genes that display a weak individual association with clinically important issues but cooperatively give an extremely precise and clinically relevant picture of the tumors. For example, in the study of Van 't Veer et al (12) on 78 breast tumor samples, around 5000 genes capable of discriminating lymph node-negative patients developing distant metastases within five years were considered for clustering analysis; the authors found a subset of only 70 genes (se-lected on the basis of their individual association with disease-free survival) that provided the optimal prediction of poor prognosis.
It is therefore conceivable that one of the products of genomewide tumor profiling will be the identification of small sets of genes that can provide all the relevant information for prognosis and prediction of response to therapy. This will possibly help resolve one of the critical points in the large-scale application of microarray analysis of tumors, i.e. the small amount of tissue available and the relative uniqueness of the analysis. If tens or a few hundreds of genes have to be analyzed, DNA microarray slides carrying a probe set printed several times on the same slide are easily conceivable, which will greatly increase the intrinsic confidence of measurements.
In breast cancer and in cancer in general, molecular characterization by DNA microarrays or other genomic or proteomic tools will shortly revolutionize the way tumors are classified and replace conventional pathological analysis. Most importantly, we will be able to tailor to each patient the most appropriate treatment among those available, in anticipation of functional genomics and biotechnology exploiting the abundance of post-genomic information to develop new targeted drugs.
